 Connection
Grover Miller to Anti-Inflammatory Agents, Non-Steroidal
This is a "connection" page, showing publications Grover Miller has written about Anti-Inflammatory Agents, Non-Steroidal.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.970 |
|
|
|
-
Schleiff MA, Crosby S, Blue M, Schleiff BM, Boysen G, Miller GP. CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs. Biochem Pharmacol. 2021 12; 194:114824.
Score: 0.726
-
Schleiff MA, Payakachat S, Schleiff BM, Swamidass SJ, Boysen G, Miller GP. Impacts of diphenylamine NSAID halogenation on bioactivation risks. Toxicology. 2021 06 30; 458:152832.
Score: 0.706
-
Barnette DA, Schleiff MA, Datta A, Flynn N, Swamidass SJ, Miller GP. Meloxicam methyl group determines enzyme specificity for thiazole bioactivation compared to sudoxicam. Toxicol Lett. 2021 Mar 01; 338:10-20.
Score: 0.680
-
Schleiff MA, Flynn NR, Payakachat S, Schleiff BM, Pinson AO, Province DW, Swamidass SJ, Boysen G, Miller GP. Significance of Multiple Bioactivation Pathways for Meclofenamate as Revealed through Modeling and Reaction Kinetics. Drug Metab Dispos. 2021 02; 49(2):133-141.
Score: 0.680
-
Datta A, Flynn NR, Barnette DA, Woeltje KF, Miller GP, Swamidass SJ. Machine learning liver-injuring drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs) from a retrospective electronic health record (EHR) cohort. PLoS Comput Biol. 2021 07; 17(7):e1009053.
Score: 0.177
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|